Karolinska Development’s portfolio company Dilafor receives patent in the US for tafoxiparin in priming of labor

Core Viewpoint - Karolinska Development's portfolio company Dilafor has received a US patent for its drug candidate tafoxiparin, which is aimed at priming labor, marking a significant step as it progresses into Phase 3 clinical trials [1][2][3]. Group 1: Patent and Development - The US Patent and Trademark Office has granted a patent for tafoxiparin, providing intellectual property protection until at least May 2043 [2]. - Tafoxiparin is designed to prepare the cervix and uterus for labor, potentially increasing the likelihood of normal vaginal deliveries and reducing the need for traditional hospital-based induction treatments [3]. - The drug is positioned to meet new national guidelines recommending labor induction at 39 weeks in the US and 40-41 weeks in Europe, which may lead to an increase in births requiring medical intervention [3]. Group 2: Company Insights - Karolinska Development holds a 3% direct ownership and a 29% indirect ownership interest in Dilafor [5]. - The CEO of Karolinska Development, Viktor Drvota, emphasized the importance of strengthening intellectual property as Dilafor advances in clinical development, highlighting the potential for a safe at-home treatment option for pregnant women [4]. - The company focuses on identifying and investing in breakthrough medical innovations in the Nordic region, aiming to create and grow companies that can deliver impactful medical products [6][8].